Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma

Withdrawn before enrolling · Phase 2

Conditions studied: Diffuse Large B Cell Lymphoma

In brief

Phase 2 single-institution trial of early systemic central nervous system prophylaxis in high-risk diffuse large B-cell lymphoma

Key facts

Study ID

NCT03719560

Run by

Brown University

People needed

0

Starts

2019-07-01

Expected to finish

2025-12-31

Last updated by the study team

2020-04-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• New diagnosis of diffuse large B-cell lymphoma, planned first-line therapy using the standard rituximab- and anthracycline-containing regimens
• No central nervous system involvement on initial staging
• Performance status of 0 or 1 (Eastern Cooperative Oncology Group scale)
• Renal function: creatinine clearance >45 ml/min
• Not pregnant; agreeable to contraception
• Written informed consent
• High risk for central nervous system recurrence as determined by one of the following high-risk features:
• high central nervous system International Prognostic Index,
• testicular, breast, or uterine involvement,
• dual expresser or double/triple-hit status,
• HIV positive status, or
• Molecularly defined high-risk subtype.

You may not qualify if…

• pregancy
• unable to provide informed consent
• significant comorbidity in the investigator's judgement

Where it is running

• Roxanne Wood — Providence, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.